PF-06882961 is primarily investigated for its potential therapeutic applications in the treatment of type 2 diabetes. It functions as a glucagon-like peptide-1 receptor (GLP-1R) agonist, which helps regulate blood sugar levels by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. This makes it a promising candidate for managing hyperglycemia in diabetic patients. Additionally, its mechanism of action may contribute to weight loss, offering a dual benefit for individuals with type 2 diabetes who often struggle with obesity. Clinical trials are ongoing to evaluate its efficacy, safety, and potential as a long-term treatment option.